3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Status
Recruiting
1
Completed
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Tumor-Agnostic
11
Gynecologic
5
Thoracic
2
Sarcoma
2
Breast
2
Other hematologic neoplasm
1
Lymphoid
1
Genitourinary
1
Gastrointestinal
1
CNS
1
Conditions
Breast Neoplasms
21
Triple Negative Breast Neoplasms
6
Ovarian Neoplasms
6
Pancreatic Neoplasms
4
Neoplasm Metastasis
3
Neoplasms
2
Fallopian Tube Neoplasms
2
Urologic Neoplasms
1
Unilateral Breast Neoplasms
1
Sarcoma
1
Prostatic Neoplasms
1
Pathologic Complete Response
1
Neoplasm, Residual
1
Metastatic Breast Cancer in Germline-PALB2 Mutations Carriers
1
Melanoma
1
Lung Neoplasms
1
Hemangiosarcoma
1
Head and Neck Neoplasms
1
HER2-negative Metastatic Breast Cancer
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Colonic Neoplasms
1
Cholangiocarcinoma
1
Interventions
Paclitaxel
26
pembrolizumab
24
Docetaxel
20
Capecitabine
19
Fulvestrant
17
Trastuzumab
16
Anastrozole
15
Cyclophosphamide
14
Lapatinib
13
Letrozole
11
Carboplatin
11
Radiotherapy
10
Doxorubicin
10
palbociclib
9
Therapeutics
9
Nivolumab
9
Exercise
9
Gemcitabine
8
Cisplatin
8
Blood Specimen Collection
8
Tamoxifen
7
Bevacizumab
7
liposomal doxorubicin
6
exemestane
6
abemaciclib
6
Vinorelbine
6
Standard of Care
6
Fluorouracil
6
atezolizumab
5
Surveys and Questionnaires
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Neoplasms
×
niraparib
×
Breast
×
Clear all
NCT01042379
2026-05-06
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2
Recruiting
5,000 enrolled
NCT02657889
2022-12-01
TOPACIO
Tesaro, Inc.
Phase 1/2
Completed
122 enrolled
29 charts